Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:PMD - Psychemedics Stock Price, Forecast & News

$9.90
+0.05 (+0.51 %)
(As of 01/24/2020 08:42 AM ET)
Today's Range
$9.82
Now: $9.90
$10.69
50-Day Range
$8.53
MA: $9.47
$10.62
52-Week Range
$7.12
Now: $9.90
$19.64
Volume22,030 shs
Average Volume17,697 shs
Market Capitalization$54.65 million
P/E Ratio18.68
Dividend Yield7.31%
Beta0.74
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.67 million
Cash Flow$1.40 per share
Book Value$3.40 per share

Profitability

Net Income$4.58 million

Miscellaneous

Employees250
Market Cap$54.65 million
Next Earnings Date3/2/2020 (Estimated)
OptionableNot Optionable

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Tuesday, October 22nd. Shareholders of record on Tuesday, November 5th will be given a dividend of $0.18 per share on Friday, November 15th. This represents a $0.72 annualized dividend and a yield of 7.27%. The ex-dividend date is Monday, November 4th. View Psychemedics' Dividend History.

How were Psychemedics' earnings last quarter?

Psychemedics Corp. (NASDAQ:PMD) issued its quarterly earnings results on Tuesday, April, 23rd. The company reported $0.11 EPS for the quarter. The company had revenue of $9.82 million for the quarter. Psychemedics had a net margin of 7.59% and a return on equity of 16.02%. View Psychemedics' Earnings History.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Psychemedics.

Has Psychemedics been receiving favorable news coverage?

Headlines about PMD stock have trended very positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Psychemedics earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Psychemedics.

Are investors shorting Psychemedics?

Psychemedics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 11,600 shares, an increase of 41.5% from the December 15th total of 8,200 shares. Based on an average trading volume of 20,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.2% of the company's stock are short sold. View Psychemedics' Current Options Chain.

Who are some of Psychemedics' key competitors?

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), AT&T (T), Dominion Energy (D), Athersys (ATHX), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Pattern Energy Group (PEGI), TrovaGene (TROV), Verastem (VSTM) and AbbVie (ABBV).

Who are Psychemedics' key executives?

Psychemedics' management team includes the folowing people:
  • Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)
  • Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)
  • Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.07%). Company insiders that own Psychemedics stock include Charles M Doucot, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.

Which institutional investors are buying Psychemedics stock?

PMD stock was acquired by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Psychemedics stock in the last two years include Charles M Doucot and Raymond C Kubacki Jr. View Insider Buying and Selling for Psychemedics.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $9.90.

How big of a company is Psychemedics?

Psychemedics has a market capitalization of $54.65 million and generates $42.67 million in revenue each year. Psychemedics employs 250 workers across the globe.View Additional Information About Psychemedics.

What is Psychemedics' official website?

The official website for Psychemedics is http://www.psychemedics.com/.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.


MarketBeat Community Rating for Psychemedics (NASDAQ PMD)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel